BEST: The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
Study Details
Study Description
Brief Summary
This study will look at the feasibility and acceptability of testing newborn babies who are referred after their newborn hearing screen for an infection called congenital Cytomegalovirus (cCMV). Around 1 in every 100 to 200 babies is born with this virus, and although most remain well it causes 1 in 5 cases of childhood deafness. Knowing that a baby is infected shortly after birth could have significant benefit since a treatment is now available, but screening programs need to be feasible and acceptable. This study aims to evaluate targeted screening for cCMV by taking samples (saliva and urine) from babies who do not pass their newborn hearing screening. The investigators want to see if we can find a quick, reliable and parentally acceptable way to screen babies who fail their hearing test for this virus.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Babies referred for further hearing tests Babies referred for further hearing tests after their neonatal hearing screening tests |
Other: Screening urine and saliva tests for congenital Cytomegalovirus
With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
|
Outcome Measures
Primary Outcome Measures
- Feasibility of targeted screening for congenital CMV [30 months]
Feasibility: as determined by proportion of urine and salivary swabs processed with a result back to parents and health professionals that would allow treatment if needed to be initiated by 28 days of age.
- Acceptability of extended screening tests [30 months]
Parental acceptability as determined by anxiety measures (in comparison to published data in parents whose infants are referred for failing their hearing screen, but where no mention of extended screening is made) and parental responses to extended questionnaires about the ease of the process of obtaining samples.
Secondary Outcome Measures
- Clinical utility of extended screening tests [30 months]
Secondary outcomes. Assess and compare the clinical utility of performing salivary and urine CMV testing on babies referred through NHSP in terms of: rate of diagnosis of cCMV by day 21 rate of initiation of treatment, where clinically indicated, by 4 weeks of age. 2. Calculate the prevalence of cCMV in children with SNHL detected following newborn hearing screening (number per population screened)
Eligibility Criteria
Criteria
Inclusion Criteria:
- All infants 'referred' for one or both ears following hospital-based newborn hearing screening in North of Tyne and South West London areas. Babies with other known causes of SNHL (e.g. hereditary) and those admitted to Neonatal Intensive Care Units will be included.
Exclusion Criteria:
- Exclusions to this study will be infants with parents/guardians not willing/able to give informed consent or children known to have congenital CMV by antenatal testing or clinical features of CMV infection at birth.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Royal Victoria Infirmary, Newcastle Hospital NHS Trust | Newcastle upon Tyne | Tyne and Wear | United Kingdom | NE1 4LP |
Sponsors and Collaborators
- Newcastle-upon-Tyne Hospitals NHS Trust
Investigators
- Study Chair: Julia Clark, Newcastle-upon-Tyne Hospitals NHS Trust
- Principal Investigator: Janet Berrington, Newcastle-upon-Tyne Hospitals NHS Trust
- Principal Investigator: Mike Sharland, St Georges Healthcare Trust
- Principal Investigator: Suzanne Luck, Royal Free Hospital NHS Foundation Trust
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5286
- 10/H0904/25